Aoki & Sachs
Docket No. 17282(AOC)

Box Seq.

PATENT

A

NEW APPLICATION TRANSMITTAL FORM

To the Assistant Commissioner for Patents:

This is a Request for filing a non-provisional patent application under 37 CFR 1.53(b) entitled METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATITIS by the following named inventors:

1	Full Name of Inventor	Last Name: SACHS	First Name: GEORGE	Middle Name:	
	Residence and Citizenship	City: ENCINO	State or Foreign Country: CALIFORNIA	Country Of Citizenship: USA	
	Post Office Address	Post Office Address: 17986 BORIS DR.	City: ENCINO	State or Country: CA	Zip Code: 91316
2	Full Name of Inventor	Last Name: AOKI	First Name: KEI	Middle Name: ROGER	
	Residence and Citizenship	City: COTO DE CAZA	State or Foreign Country: CALIFORNIA	Country Of Citizenship: USA	
	Post Office Address	Post Office Address: 2 GINGER LILY COURT	City: COTO DE CAZA	State or Country: CA	Zip Code: 92679

(X) The Commissioner is hereby authorized to use Deposit Account Number 01-0885 for the payment of any extension fees incurred during the prosecution of this application.

(X) Enclosed is a specification of 31 pages, claims 7 pages, abstract 1 page, sequence listing 7 pages.

Oath or Declaration

(X) Enclosed is an executed oath or declaration.

() Enclosed is an unsigned oath or declaration.

(X) A self-addressed return postcard is enclosed for verification of receipt.

(X) The filing fee is calculated below:

FOR	NUMBER FILED		NUMBER EXTRA		RATE	FEE
Basic Fee (Large entity)					$760	$760.00
Total Claims	40 minus 20	=	20	×	$18	360.00
Independent Claims	2 minus 3	=	0	×	$78	.00
If application contains any multiple dependent claims, then add $260.00						
			TOTAL FILING FEE			1120.00

(X) The Commissioner is hereby authorized to charge the filing fee and excess claim fees (including multiple dependent claim fee) as stated above to Deposit Account No. 01-0885. If this amount is incorrect, or for payment of any other fees that may be incurred as a result of this communication please use said Deposit Account. A duplicate copy of this sheet is enclosed for that purpose.

() A copy of an assignment bestowing all interest in this application to Allergan Sales, Inc is enclosed.

() New drawings are enclosed in __ sheets.

(X) A Statement Pursuant to 37 CFR 1.821(f) and a labeled diskette containing the computer readable sequence listing is enclosed.

() A Statement Pursuant to 37 CFR § 1.821(e), stating that the paper copy and the computer readable form are identical is filed herewith.

(X) A properly labeled computer readable form of the Sequence Listing accompanies this Application.

(X) The Power of Attorney in this application is to Carlos A. Fisher, Registration Number 36,510.

(X) The Power of Attorney appears in the combined Declaration and Power of Attorney, filed herewith.

() A copy of the Request for Extension of Time filed in the prior application is enclosed.

Please address all future communications to:

Carlos A. Fisher
Registration No. 36,510
ALLERGAN, INC.
T2-2E
2525 Dupont Drive
Irvine, CA 92623
Tel: 714-246-4920
Fax: 714-246-4249

Respectfully submitted,

Date: 4/8/99

Carlos A. Fisher
Registration No. 36,510
Attorney of Record

Aoki & Sachs
Docket No. 17282

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this paper and any documents referred to as enclosed or attached are being deposited with the United States Postal Service on this date in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL001807147US addressed to:

COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C 20231-9998
BOX PATENT APPLICATION

on 4/8/99
Date

Carlos A. Fisher
Signature of Person Making Deposit

Carlos A. Fisher
Printed Name of Person Making Deposit

Applicant: Sachs et al

Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATITIS
Allergan Docket: 17282(AOC)

Enclosed Are:

Certification Under 37 CFR 1.10 (Express Mail Label No. EL001807147US

1. POSTCARD
2. NEW APPLICATION TRANSMITTAL LETTER IN DUPLICATE
3. SPECIFICATION (31 PAGES), CLAIMS (7 PAGES), ABSTRACT (1 PAGE)
4. DECLARATION, POWER OF ATTORNEY
5. STATEMENT 37 CFR § 1.821(f)
6. SEQUENCE LISTING (7 PAGES)
7. DISKETTE

METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATITIS

Field of the Invention

The present invention includes methods and compositions for the treatment of acute pancreatitis. In a preferred embodiment the invention concerns the use of agents to reduce or prevent the secretion of pancreatic digestive enzymes within the pancreas. Such agents are targeted to pancreatic cells, and serve to prevent the exocytotic fusion of vesicles containing these enzymes with the plasma membrane. The invention is also concerned with methods of treating a mammal suffering from pancreatitis through the administration of such agents.

Background of the Invention

Pancreatitis is a serious medical condition involving an inflammation of the pancreas. In acute or chronic pancreatitis the inflammation manifests itself in the release and activation of pancreatic enzymes within the organ itself, leading to autodigestion. In many cases of acute pancreatitis, the condition can lead to death.

In normal mammals, the pancreas, a large gland similar in structure to the salivary gland, is responsible for the production and secretion of digestive enzymes, which digest ingested food, and bicarbonate for the neutralization of the acidic chyme produced in the stomach. The pancreas contains

acinar cells, responsible for enzyme production, and ductal cells, which secrete large amounts of sodium bicarbonate solution. The combined secretion product is termed "pancreatic juice"; this liquid flows through the pancreatic duct past the sphincter of Oddi into the duodenum. The secretion of pancreatic juice is stimulated by the presence of chyme in the upper portions of the small intestine, and the precise composition of pancreatic juice appears to be influenced by the types of compounds (carbohydrate, lipid, protein, and/or nucleic acid) in the chyme.

The constituents of pancreatic juice includes proteases (trypsin, chymotrypsin, carboxypolypeptidase), nucleases (RNAse and DNAse), pancreatic amylase, and lipases (pancreatic lipase, cholesterol esterase and phospholipase). Many of these enzymes, including the proteases, are initially synthesized by the acinar cells in an inactive form as zymogens: thus trypsin is synthesized as trypsinogen, chymotrypsin as chymotypsinogen, and carboxypolypeptidase as procarboxypolypeptidase. These enzymes are activated according to a cascade, wherein, in the first step, trypsin is activated through proteolytic cleavage by the enzyme enterokinase. Trypsinogen can also be autoactivated by trypsin; thus one activation has begun, the activation process can proceed rapidly. Trypsin, in turn, activates both chymotypsinogen and procarboxypolypeptidase to form their active protease counterparts.

The enzymes are normally activated only when they enter the intestinal mucosa in order to prevent autodigestion of the pancreas. In order to prevent premature activation, the

acinar cells also co-secrete a trypsin inhibitor that normally prevents activation of the proteolytic enzymes within the secretory cells and in the ducts of the pancreas. Inhibition of trypsin activity also prevents activation of the other proteases.

Pancreatitis can occur when an excess amount of trypsin saturates the supply of trypsin inhibitor. This, in turn, can be caused by underproduction of trypsin inhibitor, or the overabundance of trypsin within the cells or ducts of the pancreas. In the latter case, pancreatic trauma or blockage of a duct can lead to localized overabundance of trypsin; under acute conditions large amounts of pancreatic zymogen secretion can pool in the damaged areas of the pancreas. If even a small amount of free trypsin is available activation of all the zymogenic proteases rapidly occurs, and can lead to digestion of the pancreas (acute pancreatitis) and in particularly severe cases to the patient's death.

Pancreatic secretion is normally regulated by both hormonal and nervous mechanisms. When the gastric phase of stomach secretion occurs, parasympathetic nerve impulses are relayed to the pancreas, which initially results in acetylcholine release, followed by secretion of enzymes into the pancreatic acini for temporary storage.

When acid chyme thereafter enters the small intestine, the mucosal cells of the upper intestine release a hormone called secretin. In humans, secretin is a 27 amino acid (3400 Dalton) polypeptide initially produced as the inactive form prosecretin, which is then activated by proteolytic cleavage. Secretin is then absorbed into the blood.

Secretin causes the pancreas to secrete large quantities of a fluid containing bicarbonate ion. Secretin does not stimulate the acinar cells, which produce the digestive enzymes. The bicarbonate fluid serves to neutralize the chyme and to provide a slightly alkaline optimal environment for the enzymes.

Another peptide hormone, cholecystokinin (CCK) is released by the mucosal cells in response to the presence of food in the upper intestine. As described in further detail below, human CCK is synthesized as a protoprotein of 115 amino acids. Active CCK forms are quickly taken into the blood through the digestive tract, and normally stimulate the secretion of enzymes by the acinar cells. However, stimulation of the CCK receptor by the CCK analogs cerulein and CCK-octapeptide (CCK-8) appears to lead to a worsening of morbidity and mortality in mammals in whom pancreatitis is induced. *See* Tani et al., *Pancreas* 5:284-290 (1990).

As indicated above, the digestive enzymes are synthesized as zymogens; proto-enzyme synthesis occurs in the rough endoplasmic reticulum of the acinar cells. The zymogens are then packaged within vesicles having a single lipid bilayer membrane. The zymogens are packed within the vesicles so densely that they appear as quasi-crystalline structures when observed under light microscopy and the zymogen granules are electron-dense when observed under the electron microscope. The vesicles are localized within the cytoplasm of the acinar cells. Secretion of zymogens by the acinar cells occurs through vesicle docking and subsequent fusion with the plasma membrane, resulting in the liberation of the contents into the extracellular milieu.

Nerve cells appear to secrete neurotransmitters and other intercellular signaling factors through a mechanism of membrane fusion that is shared with other cell types, see *e.g.*, Rizo & Sudhof, *Nature Struct. Biol.* 5:839-842 (October 1998), hereby incorporated by reference herein, including the pancreatic acinar cells.

Although the Applicants do not wish to be bound by theory, it is believed that a vesicle first contacts the intracellular surface of the cellular membrane in a reaction called docking. Following the docking step the membrane fuses with and becomes part of the plasma membrane through a series of steps that currently remain relatively uncharacterized, but which clearly involve certain vesicle and membrane-associated proteins, as has been illustrated using neural models.

In neurons, neurotransmitters are packaged within synaptic vesicles, formed within the cytoplasm, then transported to the inner plasma membrane where the vesicles dock and fuse with the plasma membrane. Recent studies of nerve cells employing clostridial neurotoxins as probes of membrane fusion have revealed that fusion of synaptic vesicles with the cell membrane in nerve cells depends upon the presence of specific proteins that are associated with either the vesicle or the target membrane. *See id.* These proteins have been termed SNAREs. As discussed in further detail below, a protein alternatively termed synaptobrevin or VAMP (vesicle-associated membrane protein) is a vesicle-associated SNARE (v-SNARE). There are at least two isoforms of synaptobrevin; these two isoforms are differentially expressed in the mammalian central nervous system, and are

selectively associated with synaptic vesicles in neurons and secretory organelles in neuroendocrine cells. The target membrane-associated SNAREs (t-SNARES) include syntaxin and SNAP-25. Following docking, the VAMP protein forms a core complex with syntaxin and SNAP-25; the formation of the core complex appears to be an essential step to membrane fusion. See Rizo & Sudhof, *id.* and Neimmann et al., *Trends in Cell Biol.* 4:179-185 (May 1994), hereby incorporated by referenced herein.

Recently evidence has increasingly indicated that the SNARE system first identified in neural cells is a general model for membrane fusion in eukaryotic cells. A yeast exocytotic core complex similar to that of the synaptic vesicles of mammalian neural cells has been characterized, and found to contain three proteins: Sso 1 (syntaxin 1 homolog), SncI (synaptobrevin homolog), and sec9 (SNAP-25 homolog). Rizo & Sudhof, *id.* These proteins share a high degree of amino acid sequence homology with their mammalian synaptosomal counterparts.

All mammalian non-neuronal cells appear to contain cellubrevin, a synaptobrevin analog - this protein is involved in the intracellular transport of vesicles, and is cleaved by TeTx, BoNT/E, BoNT/F, and BoNT/G. Homologs of syntaxin have been identified in yeast (e.g., sso1p and sso2p) and mammalian non-neuronal cells (syn2p, syn3p, syn4p and syn5p). Finally, as indicated above, a yeast SNAP-25 homolog, sec9 has been identified; this protein appears to essential for vesicle fusion with the plasma membrane.

Intoxication of neural cells by clostridial neurotoxins exploits specific characteristics of the SNARE

proteins. These neurotoxins, most commonly found expressed in *Clostridium botulinum* and *Clostridium tetanus*, are highly potent and specific poisons of neural cells. These Gram positive bacteria secrete two related but distinct toxins, each comprising two disulfide-linked amino acid chains: a light chain (L) of about 50 KDa and a heavy chain (H) of about 100 KDa, which are wholly responsible for the symptoms of botulism and tetanus, respectively.

The tetanus and botulinum toxins are among the most lethal substances known to man; both toxins function by inhibiting neurotransmitter release in affected neurons. The tetanus neurotoxin (TeNT) acts mainly in the central nervous system, while botulinum neurotoxin (BoNT) acts at the neuromuscular junction; both toxins inhibit acetylcholine release from the nerve terminal of the affected neuron into the synapse, resulting in paralysis or reduced target organ function.

The tetanus neurotoxin (TeNT) is known to exist in one immunologically distinct type; the botulinum neurotoxins (BoNT) are known to occur in seven different immunologically distinct serotypes, termed BoNT/A through BoNT/G. While all of these latter types are produced by isolates of *C. botulinum*, two other species, *C. baratii* and *C. butyricum* also produce toxins similar to /F and /E, respectively. *See* e.g., Coffield et al., *The Site and Mechanism of Action of Botulinum Neurotoxin* in *Therapy with Botulinum Toxin* 3-13 (Jankovic J. & Hallett M. eds. 1994), the disclosure of which is incorporated herein by reference.

Regardless of type, the molecular mechanism of intoxication appears to be similar. In the first step of

the process, the toxin binds to the presynaptic membrane of the target neuron through a specific interaction between the heavy chain and a neuronal cell surface receptor; the receptor is thought to be different for each type of botulinum toxin and for TeNT. The carboxy terminal (C-terminal) half of the heavy chain is required for targeting of the toxin to the cell surface. The cell surface receptors, while not yet conclusively identified, appear to be distinct for each neurotoxin serotype.

In the second step, the toxin crosses the plasma membrane of the poisoned cell. The toxin is first engulfed by the cell through receptor-mediated endocytosis, and an endosome containing the toxin is formed. The toxin (or light chain thereof) then escapes the endosome into the cytoplasm of the cell. This last step is thought to be mediated by the amino terminal (N-terminal) half of the heavy chain, which triggers a conformational change of the toxin in response to a pH of about 5.5 or lower. Endosomes are known to possess a proton pump that decreases intra-endosomal pH. The conformational shift exposes hydrophobic residues in the toxin, which permits the toxin to embed itself in the endosomal membrane. The toxin then translocates through the endosomal membrane into the cytosol.

Either during or after translocation the disulfide bond joining the heavy and light chain is reduced, and the light chain is released into the cytoplasm. The entire toxic activity of botulinum and tetanus toxins is contained in the light chain of the holotoxin; the light chain is a zinc (Zn++) endopeptidase which selectively cleaves the SNARE

proteins essential for recognition and docking of neurotransmitter-containing vesicles with the cytoplasmic surface of the plasma membrane, and fusion of the vesicles with the plasma membrane. The light chain of TxNT, BoNT/B, BoNT/D, BoNT/F, and BoNT/G cause specific proteolysis of VAMP, an integral protein. During proteolysis, most of the VAMP present at the cytosolic surface of the synaptic vesicle is inactivated as a result of any one of these cleavage events. Each toxin cleaves a different specific peptide bond.

BoNT/A and /E selectively cleave the plasma membrane-associated SNARE protein SNAP-25; this protein is bound to and present on the cytoplasmic surface of the plasma membrane. BoNT/C1 cleaves syntaxin, which exists as an integral protein having most of its mass exposed to the cytosol. Syntaxin interacts with the calcium channels at presynaptic terminal active zones. *See* Tonello et al., *Tetanus and Botulism Neurotoxins in Intracellular Protein Catabolism* 251-260 (Suzuki K & Bond J. eds. 1996), the disclosure of which is incorporated by reference as part of this specification. Bo/NTC1 also appears to cleave SNAP-25.

Both TeNT and BoNT are specifically taken up by cells present at the neuromuscular junction. BoNT remains within peripheral neurons and, as indicated above, blocks release of the neurotransmitter acetylcholine from these cells.

By contrast TeNT, through its receptor, enters vesicles that move in a retrograde manner along the axon to the soma, and is discharged into the intersynaptic space between motor neurons and the inhibitory neurons of the spinal cord. At this point, TeNT binds receptors of the inhibitory neurons,

is again internalized, and the light chain enters the cytosol to block the release of the inhibitory neurotransmitters 4-aminobutyric acid (GABA) and glycine from these cells. Id.

International Patent Publication No. WO 96/33273 relates to derivatives of botulinum toxin designed to prevent neurotransmitter release from sensory afferent neurons to treat chronic pain. Such derivatives are targeted to nociceptive neurons using a targeting moiety that binds to a binding site of the surface of the neuron.

International Patent Publication No. 98/07864 discusses the production of recombinant toxin fragments that have domains that enable the polypeptide to translocate into a target cell or which increase the solubility of the polypeptide, or both.

Summary of the Invention

The present invention concerns methods and compositions useful for the treatment of acute pancreatitis. This condition is largely due to the defective secretion of zymogen granules by acinar cells, and by the premature co-mingling of the secreted zymogens with lysosomal hydrolysates capable of activating trypsin, thereby triggering the protease activation cascade and resulting in the destruction of pancreatic tissue.

In one embodiment of this aspect, the invention is a therapeutic agent comprising a chimeric protein containing an amino acid sequence-specific endopeptidase activity which

will specifically cleave at least one synaptic vesicle-associated protein selected from the group consisting of SNAP-25, syntaxin or VAMP, in combination with the translocation activity of the N-terminus of a clostridial neurotoxin heavy chain, wherein the chimeric protein further comprises a recognition domain which will bind a human cholecystokinin (CCK) receptor. Upon binding of the recognition domain of the protein to the CCK receptor, the protein is specifically transported into cells containing CCK receptors (pancreatic acinar cells) through receptor-mediated endocytosis. In a preferred embodiment, the CCK receptor is the CCK A receptor.

Once inside the acinar cell, the chimeric protein functions in a manner similar to that of a clostridial neurotoxin within its target neuron. The toxin moiety is translocated from the endosome into the cytoplasm, where it acts to cleave a SNARE protein identical or homologous to SNAP-25, syntaxin or VAMP. The cleavage of this protein prevents formation of a core complex between the SNARE proteins and thus prevents or reduces the extent of fusion of the vesicle with the target membrane. This, in turn, results in inhibition of zymogen release from the acinar cells and of zymogen activation by lysosomal hydrolases. The autodigestion of pancreatic tissue in acute pancreatitis is therefore reduced or eliminated.

Another embodiment of the present invention concerns a method of treating a patient suffering from acute pancreatitis by administering an effective amount of such a chimeric protein.

Another embodiment of the invention concerns a

therapeutic composition that contains the translocation activity of a clostridial neurotoxin heavy chain in combination with a recognition domain able to bind a specific cell type and a therapeutic element having an activity other than the endopeptidase activity of a clostridial neurotoxin light chain. A non-exclusive list of certain such therapeutic elements includes: hormones and hormone-agonists and antagonists, nucleic acids capable being of being used as replication, transcription, or translational templates (e.g., for expression of a protein drug having the desired biological activity or for synthesis of a nucleic acid drug as an antisense agent), enzymes, toxins, and the like.

In a preferred embodiment, the specific cell type is a pancreatic cell, most preferably a pancreatic acinar cell.

Another embodiment is drawn to methods for the treatment of acute pancreatitis comprising contacting an acinar cell with an effective amount of a composition comprising a chimeric protein containing an amino acid sequence-specific endopeptidase activity which will specifically cleave at least one synaptic vesicle-associated protein selected from the group consisting of SNAP-25, syntaxin or VAMP, in combination with the translocation activity of the N-terminus of a clostridial neurotoxin heavy chain, wherein the chimeric protein further comprises a recognition domain able to bind to a cell surface protein characteristic of an human pancreatic acinar cell. Preferably the cell surface protein is a CCK receptor protein; most preferably the protein is the human CCK A protein. CCK receptors (CCK-A receptor and CCK-B receptor)

are found mainly in on the surface of pancreatic acinar cells, although they are also found in some brain cells and, to a lesser extent on the surface of gastrointestinal cells.

Any suitable route of administration may be used in this aspect of the invention. Applicants currently prefer to administer the therapeutic agent in an intravenous infusion solution; however methods such as ingestion (particularly when associated with neurotoxin-associated proteins (NAPs); *see* Sharma et al., *J. Nat. Toxins* 7:239-253(1998), incorporated by reference herein), direct delivery to the pancreas, injection and the like may also be used. The agent is substantially specifically targeted to pancreatic cells; when the agent contains a CCK receptor-binding domain, the blood-brain barrier prevents the agent from interacting with brain cells.

In yet another embodiment the invention provides a composition comprising a drug or other therapeutic agent having an activity other than that of a clostridial neurotoxin light chain for intracellular delivery, said agent joined to the translocation domain of a clostridial neurotoxin heavy chain and a binding element able to recognize a cell surface receptor of a target cell. In a preferred embodiment, the target cell is not a neuron. Also, in this embodiment it is preferred that the drug or other therapeutic agent has an enzymatic, catalytic, or other self-perpetuating mode of activity, so that the effective dose of drug is greater than the number of drug molecules delivered within the target cell. A non-exclusive list of certain such drugs would include: hormones and hormone-agonists and antagonists, nucleic acids capable

being of being used as replication, transcription, or translational templates (e.g., for expression of a protein drug having the desired biological activity or for synthesis of a nucleic acid drug as an antisense agent), enzymes, toxins (such as diphtheria toxin or ricin), and the like.

In this embodiment the drug may be cleavably linked to the remainder of the composition in such a way as to allow for the release of the drug from the composition within the target cell.

The presently claimed compositions may be provided to the patient by intravenous administration, may be administered during surgery, or may be provided parenterally.

WO 95/32738, which is shares ownership with the present application, describes transport proteins for the therapeutic treatment of neural cells. This application is incorporated by reference herein as part of this specification.

Detailed Description of the Preferred Embodiments

In a basic and presently preferred form, the invention comprises a therapeutic polypeptide comprising three features: a binding element, a translocation element, and a therapeutic element.

The binding element is able to bind to a specific target cell provided that the target cell is not a motor neuron or a sensory afferent neuron. Preferably, the binding element comprises an amino acid chain; also an independently, it is preferably located at or near the C-

terminus of a polypeptide chain. By "binding element" is meant a chemical moiety able to preferentially bind to a cell surface marker characteristic of the target cell under physiological conditions. The cell surface marker may comprise a polypeptide, a polysaccharide, a lipid, a glycoprotein, a lipoprotein, or may have structural characteristics of more than one of these. By "preferentially interact" is meant that the disassociation constant (K_d) of the binding element for the cell surface marker is at least one order of magnitude less than that of the binding element for any other cell surface marker. Preferably, the disassociation constant is at least 2 orders of magnitude less, even more preferably the disassociation constant is at least 3 orders of magnitude less than that of the binding element for any other cell surface marker to which the therapeutic polypeptide is exposed. Preferably, the organism to be treated is a human.

In one embodiment the cell surface receptor comprises the histamine receptor, and the binding element comprises an variable region of an antibody which will specifically bind the histamine receptor.

In an especially preferred embodiment, the cell surface marker is a cholecystokinin (CCK) receptor. Cholecystokinin is a bioactive peptide that functions as both a hormone and a neurotransmitter in a wide variety of physiological settings. Thus, CCK is involved in the regulation of gall bladder contraction, satiety, gastric emptying, and gut motility; additionally it is involved in the regulation of pancreatic exocrine secretion.

There are two types of CCK receptors, CCK A and CCK B; the amino acid sequences of these receptors have been determined from cloned cDNA. Despite the fact that both receptors are G protein-coupled receptors and share approximately 50% homology, there are distinct differences between their physiological activity. The CCK A receptor is expressed in smooth muscle cells of the gall bladder, smooth muscle and neurons within the gastrointestinal tract, and has a much greater affinity (>10^2 times higher) for CCK than the related peptide hormone gastrin. The CCK B receptor, found in the stomach and throughout the CNS, has roughly equal ability to bind CCK and gastrin.

The varied activities of CCK can be partly attributed to the fact that CCK is synthesized as procholecystokinin, a protoprotein of 115 amino acids, and is then post-translationally cleaved into a number of active fragments all sharing the same C-terminus. The amino acid sequence of human procholecystokinin is shown below; amino acid residues not present in the biologically active cleavage products are in lower case. All amino acid sequences herein are shown from N-terminus to C-terminus, unless expressly indicated otherwise:

Human procholecystokinin, having the amino acid sequence SEQ ID NO:1:

mnsgvclcvlmavlaagaltqpvppadpagsglqraeeaprrqlr VSQRT DGESRAHLGA LLARYIQQAR KAPSGRMSIV KNLQNLDPSH RISDRDYMGW MDF grrsaeeyeyps

Biologically active cleavage products of the full length CCK chain include:

CCK-58, having the amino acid sequence SEQ ID NO:2:

VSQRT DGESRAHLGA LLARYIQQAR KAPSGRMSIV KNLQNLDPSH RISDRDYMGW MDF;

CCK-39, having the amino acid sequence SEQ ID NO: 3:

YIQQAR KAPSGRMSIV KNLQNLDPSH RISDRDYMGW MDF;

CCK-33, having the amino acid sequence SEQ ID NO: 4:

KAPSGRMSIV KNLQNLDPSH RISDRDYMGW MDF;

CCK-12, having the amino acid sequence SEQ ID NO: 5:

ISDRDYMGW MDF;

and CCK-8, having the amino acid sequence SEQ ID NO: 6:

RDYMGW MDF.

In each case, the biologically active polypeptides contain two additional post-translational modifications; amidation of the C-terminal phenylalanine, and sulfatation of the aspartic acid residue located seven residue from the C-terminus of the biologically active species. These modifications appear to be necessary for full biological activity, although both the C-terminal pentapeptide and tetrapeptide of CCK retains some biological activity.

Kennedy et al., *J. Biol. Chem.* 272: 2920-2926 (1997), hereby incorporated by reference herein.

While it will be understood that the applicants do not wish to be bound by theory, the following findings may assist an understanding the nature of the interaction between CCK and the CCK receptors, and thus between the CCK receptor binding element of an embodiment of the present invention and its CCK receptor target.

In pancreatic acinar cells the CCK A receptor undergoes internalization to intracellular sites within minutes after agonist exposure. Pohl et al., *J. Biol. Chem.* 272: 18179-18184 (1997), hereby incorporated by reference herein. The CCK B receptor has also shown the same ligand-dependant internalization response in transfected NIH 3T3 cells. In the CCK B receptor, but not the CCK A receptor, the endocytotic feature of the receptor been shown to be profoundly decreased by the deletion of the C terminal 44 amino acids of the receptor chain, corresponding in both receptors to an cytoplasmic portion of the receptor chain.

Recent studies of the interaction between the CCK A receptor and CCK have shown that the primary receptor sequence region containing amino acid residues 38 through 42 is involved in the binding of CCK. Residues Trp_{39} and Gln_{40} appear to be essential for the binding of a synthetic CCK C-terminal nonapeptide (in which the methionine residues located at residue 3 and 6 from the C-terminus are substituted by norleucine and threonine respectively) to the receptor. Kennedy et al., *supra*. These residues do not appear to be essential for the binding of CCK analogs JMV 180 (corresponding the synthetic C-terminal heptapeptide of

CCK in which the phenylalanylamide residue is substituted by a phenylethyl ester and the threonine is substituted with norleucine), and JMV 179 (in which the phenylalanylamide residue and the L-tryptophan residues of the synthetic CCK nonapeptide are substituted by a phenylethyl ester and D-tryptophan, respectively and the threonine is substituted with norleucine). *Id.*

These and similar studies have shed light on the structure of the CCK A receptor active site. Based on receptor binding experiments, a current structural model indicates that CCK residues Trp_{30} and Met_{31} (located at positions 4 and 3, respectively, from the C terminus of mature CCK-8) reside in a hydrophobic pocket formed by receptor residues Leu_{348}, Pro_{352}, Ile_{353} and Ile_{356}. CCK residue Asp_{32} (located at amino acid position 2 measured from the C terminus of CCK-8) seems to be involved in an ionic interaction with receptor residue Lys_{115}. CCK Tyr-sulfate$_{27}$ (the CCK-8 residue 7 amino acids from C terminus) appears involved in an ionic interaction with receptor residue Lys_{105} and a stacking interaction with receptor residue Phe_{198}. Ji, et al., 272 *J. Biol. Chem.* 24393-24401 (1997).

Such structural models provide detailed guidance to the person of ordinary skill in the art as to the construction of a variety of binding elements able to retain the binding characteristics of biologically active CCK peptides for the CCK-A receptor, for example, as, for example, by site directed mutagenesis of a clostridial neurotoxin heavy chain. Similarly, models deduced using similar methodologies have been proposed for the CCK B receptor, see e.g.,

Jagerschmidt, A. et al., *Mol. Pharmacol.* 48:783-789 (1995), and can be used as a basis for the construction of binding elements that retain binding characteristics similar to the CCK B receptor.

Additionally, the binding element may comprise a variable region of an antibody which will bind the CCK-A or CCK-B receptor.

Nucleic acids encoding polypeptides containing such a binding element may be constructed using molecular biology methods well known in the art; see e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory Press 2d ed. 1989), and expressed within a suitable host cell. The disclosure of this latter reference is incorporated by reference herein in its entirety.

The translocation element comprises a portion of a clostridial neurotoxin heavy chain having a translocation activity. By "translocation" is meant the ability to facilitate the transport of a polypeptide through a vesicular membrane, thereby exposing some or all of the polypeptide to the cytoplasm.

In the various botulinum neurotoxins translocation is thought to involve an allosteric conformational change of the heavy chain caused by a decrease in pH within the endosome.

This conformational change appears to involve and be mediated by the N terminal half of the heavy chain and to result in the formation of pores in the vesicular membrane; this change permits the movement of the proteolytic light chain from within the endosomal vesicle into the cytoplasm.

See e.g., Lacy, et al., *Nature Struct. Biol.* 5:898-902 (October 1998).

The amino acid sequence of the translocation-mediating portion of the botulinum neurotoxin heavy chain is known to those of skill in the art; additionally, those amino acid residues within this portion that are known to be essential for conferring the translocation activity are also known.

It would therefore be well within the ability of one of ordinary skill in the art, for example, to employ the naturally occurring N-terminal peptide half of the heavy chain of any of the various *Clostridium tetanus* or *Clostridium botulinum* neurotoxin subtypes as a translocation element, or to design an analogous translocation element by aligning the primary sequences of the N-terminal halves of the various heavy chains and selecting a consensus primary translocation sequence based on conserved amino acid, polarity, steric and hydrophobicity characteristics between the sequences.

The therapeutic element of the present invention may comprise, without limitation: active or inactive (i.e., modified) hormone receptors (such as androgen, estrogen, retinoid, perioxysome proliferator and ecdysone receptors etc.), and hormone-agonists and antagonists, nucleic acids capable being of being used as replication, transcription, or translational templates (e.g., for expression of a protein drug having the desired biological activity or for synthesis of a nucleic acid drug as an antisense agent), enzymes, toxins (including apoptosis-inducing agents), and the like.

In a preferred embodiment, the therapeutic element is a polypeptide comprising a clostridial neurotoxin light chain or a portion thereof retaining the SNARE-protein sequence-specific endopeptidase activity of a clostridial neurotoxin light chain. The amino acid sequences of the light chain of botulinum neurotoxin (BoNT) subtypes A-G have been determined, as has the amino acid sequence of the light chain of the tetanus neurotoxin (TeNT). Each chain contains the Zn^{++}-binding motif **His-Glu-x-x-His** (N terminal direction at the left) characteristic of Zn^{++}-dependent endopeptidases (HELIH in TeNT, BoNT/A /B and /E; HELNH in BoNT/C; and HELTH in BoNT/D).

Recent studies of the BoNT/A light chain have revealed certain features important for the activity and specificity of the toxin towards its target substrate, SNAP-25. Thus, studies by Zhou et al. *Biochemistry* 34:15175-15181 (1995) have indicated that when the light chain amino acid residue His_{227} is substituted with tyrosine, the resulting polypeptide is unable to cleave SNAP-25; Hurazono et al., *J. Biol. Chem.* 14721-14729 (1992) performed studies in the presynaptic cholinergic neurons of the buccal ganglia of *Aplysia californica* using recombinant BoNT/A light chain that indicated that the removal of 10 N-terminal or 32 C-terminal residues did not abolish toxicity, but that removal of 10 N-terminal or 57 C-terminal residues abolished toxicity in this system. Most recently, the crystal structure of the entire BoNT/A holotoxin has been solved; the active site is indicated as involving the participation of His_{222}, Glu_{223}, His_{226}, Glu_{261} and Tyr_{365}. Lacy et al., *supra*.

(These residues correspond to His_{223}, Glu_{224}, His_{227}, Glu_{262} and Tyr_{366} of the BoNT/A L chain of Kurazono et al., *supra*.) Interestingly, an alignment of BoNT/A through E and TeNT light chains reveals that every such chain invariably has these residues in positions analogous to BoNT/A. Kurazono et al., *supra*.

The catalytic domain of BoNT/A is very specific for the C-terminus of SNAP-25 and appears to require a minimum of 16 SNAP-25 amino acids for cleavage to occur. The catalytic site resembles a pocket; when the light chained is linked to the heavy chain via the disulfide bond between Cys_{429} and Cys_{453}, the translocation domain of the heavy chain appears to block access to the catalytic pocket until the light chain gains entry to the cytosol. When the disulfide bond is reduced, the two polypeptide chains dissociate, and the catalytic pocket is then "opened" and the light chain is fully active.

As described above, VAMP and syntaxin are cleaved by BoNT/B, D, F, G and TeNT, and BoNT/C_1, respectively, while SNAP-25 is cleaved by BoNT/A and E.

The substrate specificities of the various clostridial neurotoxin light chains other than BoNT/A are known. Therefore, the person of ordinary skill in the art could easily determine the toxin residues essential in these subtypes for cleavage and substrate recognition (for example, by site-directed mutagenesis or deletion of various regions of the toxin molecule followed by testing of proteolytic activity and substrate specificity), and could

therefore easily design variants of the native neurotoxin light chain that retain the same or similar activity.

Additionally, construction of the therapeutic agents set forth in this specification would be easily constructed by the person of skill in the art. It is well known that the clostridial neurotoxins have three functional domains analogous to the three elements of the present invention. For example, the BoNT/A neurotoxin light chain is present in amino acid residues 1-448 of the BoNT/A prototoxin (i.e., before nicking of the prototoxin to form the disulfide-linked dichain holotoxin); this amino acid sequence is provided below as SEQ ID NO: 7. Active site residues are underlined:

BoNT/A light chain (SEQ ID NO:7)

MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWV
IPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTD
LGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADI
IQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPA
VTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDS
LQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVD
KLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNL
RNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNK;

The heavy chain N-terminal (H_N) translocation domain is contained in amino acid residues 449-871 of the BoNT/A amino acid sequence, shown below as SEQ ID NO: 8; a gated ion channel-forming domain probably essential for the translocation activity of this peptide is underlined (see Oblatt-Montal et al., *Protein Sci.* 4:1490-1497(1995), hereby incorporated by reference herein.

ALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNF
DNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMFHYLRAQEFEHGKSRI
ALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTT
DKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGAVILLEFIPEIAIPVLGTFALV
SYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQA
EATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMN
SMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKY
VDNQRLLSTFTEYIK;

The heavy chain C-terminal neural cell binding domain is contained in amino acid residues 872-1296 (SEQ ID NO: 9) of the BoNT/A prototoxin.

NIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQI
QLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNS
GWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIY
INGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLY
DNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTT
NIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAGVEK
ILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLV
ASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL

The amino acid sequence of the BoNT/A prototoxin is encoded by nucleotides 358 to 4245 of the neurotoxin cDNA sequence, set forth herein below as SEQ ID NO: 10.

aagcttctaa atttaaatta ttaagtataa atccaaataa acaatatgtt caaaaacttg
atgaggtaat aatttctgta ttagataata tggaaaaata tatagatata tctgaagata
atagattgca actaatagat aacaaaaata acgcaaagaa gatgataatt agtaatgata
tatttatttc caattgttta accctatctt ataacggtaa atatatatgt ttatctatga
aagatgaaaa ccataattgg atgatatgta ataatgatat gtcaaagtat ttgtatttat
ggtcatttaa ataattaata atttaattaa ttttaaatat tataagaggt gttaaatatg
ccatttgtta ataaacaatt taattataaa gatcctgtaa atggtgttga tattgcttat
ataaaaattc caaatgcagg acaaatgcaa ccagtaaaag cttttaaaat tcataataaa
atatgggtta ttccagaaag agatacattt acaaatcctg aagaaggaga tttaaatcca
ccaccagaag caaaacaagt tccagtttca tattatgatt caacatattt aagtacagat
aatgaaaaag ataattattt aaagggagtt acaaaattat ttgagagaat ttattcaact
gatcttggaa gaatgttgtt aacatcaata gtaaggggaa taccattttg gggtggaagt
acaatagata cagaattaaa agttattgat actaattgta ttaatgtgat acaaccagat
ggtagttata gatcagaaga acttaatcta gtaataatag gaccctcagc tgatattata
cagtttgaat gtaaaagctt tggacatgaa gttttgaatc ttacgcgaaa tggttatggc
tctactcaat acattagatt tagcccagat tttacatttg gttttgagga gtcacttgaa

gttgatacaa atcctctttt aggtgcaggc aaatttgcta cagatccagc agtaacatta
gcacatgaac ttatacatgc tggacataga ttatatggaa tagcaattaa tccaaatagg
gtttttaaag taaatactaa tgcctattat gaaatgagtg ggttagaagt aagctttgag
gaacttagaa catttggggg acatgatgca aagtttatag atagtttaca ggaaaacgaa
tttcgtctat attattataa taagtttaaa gatatagcaa gtacacttaa taaagctaaa
tcaatagtag gtactactgc ttcattacag tatatgaaaa atgttttaa agagaaatat
ctcctatctg aagatacatc tggaaaattt tcggtagata aattaaaatt tgataagtta
tacaaaatgt taacagagat ttacacagag gataattttg ttaagttttt taaagtactt
aacagaaaaa catatttgaa ttttgataaa gccgtattta agataaatat agtacctaag
gtaaattaca caatatatga tggatttaat ttaagaaata caaatttagc agcaaacttt
aatggtcaaa atacagaaat taataatatg aattttacta aactaaaaaa ttttactgga
ttgtttgaat tttataagtt gctatgtgta agagggataa taacttctaa aactaaatca
ttagataaag gatacaataa ggcattaaat gatttatgta tcaaagttaa taattgggac
ttgtttttta gtccttcaga agataatttt actaatgatc taaataaagg agaagaaatt
acatctgata ctaatataga agcagcagaa gaaaatatta gtttagattt aatacaacaa
tattatttaa cctttaattt tgataatgaa cctgaaaata tttcaataga aaatctttca
agtgacatta taggccaatt agaacttatg cctaatatag aaagatttcc taatggaaaa
aagtatgagt tagataaata tactatgttc cattatcttc gtgctcaaga atttgaacat
ggtaaatcta ggattgcttt aacaaattct gttaacgaag cattattaaa tcctagtcgt
gtttatacat ttttttcttc agactatgta aagaaagtta ataaagctac ggaggcagct
atgtttttag gctgggtaga acaattagta tatgatttta ccgatgaaac tagcgaagta
agtactacgg ataaaattgc ggatataact ataattattc catatatagg acctgcttta
aatataggta atatgttata taaagatgat tttgtaggtg ctttaatatt ttcaggagct
gttattctgt tagaatttat accagagatt gcaatacctg tattaggtac ttttgcactt
gtatcatata ttgcgaataa ggttctaacc gttcaaacaa tagataatgc tttaagtaaa
agaaatgaaa aatgggatga ggtctataaa tatatagtaa caaattggtt agcaaaggtt
aatacacaga ttgatctaat aagaaaaaaa atgaaagaag ctttagaaaa tcaagcagaa
gcaacaaagg ctataataaa ctatcagtat aatcaatata ctgaggaaga gaaaaataat
attaatttta atattgatga tttaagttcg aaacttaatg agtctataaa taaagctatg
attaatataa ataaattttt gaatcaatgc tctgtttcat atttaatgaa ttctatgatc
ccttatggtg ttaaacggtt agaagatttt gatgctagtc ttaaagatgc attattaaag
tatatatatg ataatagagg aactttaatt ggtcaagtag atagattaaa agataaagtt
aataatacac ttagtacaga tatacctttt cagctttcca aatacgtaga taatcaaaga
ttattatcta catttactga atatattaag aatattatta atacttctat attgaattta
agatatgaaa gtaatcattt aatagactta tctaggtatg catcaaaaat aaatattggt
agtaaagtaa attttgatcc aatagataaa aatcaaattc aattatttaa tttagaaagt
agtaaaattg aggtaatttt aaaaaatgct attgtatata atagtatgta tgaaaatttt
agtactagct tttggataag aattcctaag tattttaaca gtataagtct aaataatgaa
tatacaataa taaattgtat ggaaaataat tcaggatgga aagtatcact taattatggt
gaaataatct ggactttaca ggatactcag gaaataaaac aaagagtagt ttttaaatac
agtcaaatga ttaatatatc agattatata aacagatgga tttttgtaac tatcactaat
aatagattaa ataactctaa aatttatata aatggaagat taatagatca aaaaccaatt
tcaaatttag gtaatattca tgctagtaat aatataatgt ttaaattaga tggttgtaga
gatacacata gatatatttg gataaaatat tttaatcttt ttgataagga attaaatgaa
aaagaaatca aagatttata tgataatcaa tcaaattcag gtattttaaa agacttttgg
ggtgattatt tacaatatga taaaccatac tatatgttaa atttatatga tccaaataaa
tatgtcgatg taaataatgt aggtattaga ggttatatgt atcttaaagg gcctagaggt
agcgtaatga ctacaaacat ttatttaaat tcaagtttgt atagggggac aaaatttatt
ataaaaaaat atgcttctgg aaataaagat aatattgtta gaaataatga tcgtgtatat

attaatgtag tagttaaaaa taaagaatat aggttagcta ctaatgcatc acaggcaggc
gtagaaaaaa tactaagtgc attagaaata cctgatgtag gaaatctaag tcaagtagta
gtaatgaagt caaaaaatga tcaaggaata acaaataaat gcaaaatgaa tttacaagat
aataatggga atgatatagg ctttatagga tttcatcagt ttaataatat agctaaacta
gtagcaagta attggtataa tagacaaata gaaagatcta gtaggacttt gggttgctca
tgggaattta ttcctgtaga tgatggatgg ggagaaaggc cactgtaatt aatctcaaac
tacatgagtc tgtcaagaat tttctgtaaa catccataaa aattttaaaa ttaatatgtt
taagaataac tagatatgag tattgtttga actgcccctg tcaagtagac aggtaaaaaa
ataaaaatta agatactatg gtctgatttc gatattctat cggagtcaga ccttttaact
tttcttgtat ccttttttgta ttgtaaaact ctatgtattc atcaattgca agttccaatt
agtcaaaatt atgaaacttt ctaagataat acatttctga ttttataatt tcccaaaatc
cttccatagg accattatca atacatctac caactcgaga catactttga gttgcgccta
tctcattaag tttattcttg aaagatttac ttgtatattg aaaaccgcta tcactgtgaa
aaagtggact agcatcagga ttggaggtaa ctgctttatc aaaggtttca aagacaagga
cgttgttatt tgattttcca agtacatagg aaataatgct attatcatgc aaatcaagta
tttcactcaa gtacgccttt gtttcgtctg ttaac

Of course, three distinct domains analogous to those described above for BoNT/A exist for all the BoNT subtypes as well as for TeNT neurotoxin; an alignment of the amino acid sequences of these holotoxins will reveal the sequence coordinates for these other neurotoxin species.

Preferably, the translocation element and the binding element of the compositions of the present invention are separated by a spacer moiety that facilitates the binding element's binding to the desired cell surface receptor. Such a spacer may comprise, for example, a portion of the BoNT Hc sequence (so long as the portion does not retain the ability to bind to motor neurons or sensory afferent neurons), another sequence of amino acids, or a hydrocarbon moiety. The spacer moiety may also comprise a proline, serine, threonine and/or cysteine-rich amino acid sequence similar or identical to a human immunoglobulin hinge region. In a preferred embodiment, the spacer region comprises the amino acid sequence of an immunoglobulin γ1 hinge region; such a sequence has the sequence (from N terminus to C terminus):

EPKSCDKTHTCPPCP (SEQ ID NO:11)

It will be understood that none of the examples or embodiments described herein are to be construed as limiting the scope of the invention, which is defined solely by the claims that conclude this specification.

Example 1:

An agent for the treatment of acute pancreatitis is constructed as follows.

A culture of *Clostridium botulinum* is permitted to grown to confluence. The cells are then lysed and total RNA is extracted according to conventional methods and in the presence of an RNAse inhibitor. The RNA preparation is then passed over a oligo(dT) cellulose column, the polyadenylated messenger RNA is permitted to bind, and the column is washed with 5-10 column volumes of 20 mM Tris pH 7.6, 0.5 M NaCl, 1 mM EDTA (ethylenediamine tetraacetic acid), 0.1% (w/v)SDS (sodium dodecyl sulfate). Polyadenylated RNA is then eluted with 2-3 column volumes of STE (10 mM Tris (pH 7.6), 1 mM EDTA, 0.05% (w/v) SDS). The pooled mRNA is then precipitated in 2 volumes of ice cold ethanol, pelleted in a centrifuge at 10,000 x g for 15 minutes, then redissolved in a small volume of STE.

The BoNT/A mRNA is used as a template for DNA synthesis using Moloney murine leukemia virus reverse transcriptase (MMLV-RT), then the L chain and then H_N chain of the neurotoxin is amplified from the cDNA by the polymerase chain reaction (PCR) using appropriate oligonucleotide primers whose sequences are designed based on the BoNT/A

neurotoxin cDNA sequence of SEQ ID NO: 9. These procedures are performed using the standard techniques of molecular biology as detailed in, for example, Sambrook et al., already incorporated by reference herein. The primer defining the beginning of the coding region (5'side of the L chain fragment) is given a StuI site. The PCR primer defining the 3' end of the H_N-encoding domain has the following features (from 3' to 5'): a 5' region sufficiently complementary to the 3' end of the H_N-encoding domain to anneal thereto under amplification conditions, a nucleotide sequence encoding the human immunoglobulin hinge region γ_1 (SEQ ID NO:11), a nucleotide sequence encoding the human CCK-8 octapeptide (SEQ ID NO:6), and a unique restriction endonuclease cleavage site.

The PCR product (termed BoNT/$A^{L\text{-}HN\text{-}\gamma\text{-}CCK}$) is purified by agarose gel electrophoresis, and cloned into a pBluescript II SK vector. The resulting plasmid is used to transform competent *E. coli* cells, and a preparation of the resulting plasmid is made. The BoNT/$A^{L\text{-}HN\text{-}\gamma\text{-}CCK}$ fragment is excised from the pBluescript vector and cloned into a mammalian expression vector immediately downstream of a strong promoter. The resulting vector is used to transfect a culture of the appropriate host cell, which is then grown to confluence. Expression of the BoNT/$A^{L\text{-}HN\text{-}\gamma\text{-}CCK}$ polypeptide is induced, and the cells are lysed. The polypeptide is first purified by gel exclusion chromatography, the fractions containing the recombinant therapeutic agent are pooled, then the BoNT/$A^{L\text{-}HN\text{-}\gamma\text{-}CCK}$ polypeptide is further purified using

an anti-Ig affinity column wherein the antibody is directed to the γ_1 hinge region of a human immunoglobulin.

Example 2: Method of Treating a Patient Suffering from Acute Pancreatitis

A therapeutically effective amount of the BoNT/$A^{L\text{-}HN\gamma\text{-}CCK}$ agent constructed and purified as set forth in Example 1 is formulated in an acceptable infusion solution. Properties of pharmacologically acceptable infusion solutions, including proper electrolyte balance, are well known in the art. This solution is provided intravenously to a patient suffering from acute pancreatitis on a single day over a period of one to two hours. Additionally, the patient is fed intravenously on a diet low in complex carbohydrates, complex fats and proteins.

At the beginning of treatment, the patient's pancreas shows signs of autodigestion, as measured by blood amylase levels. After the treatment regimen, autodigestion has ceased, and the patient's pancreas has stabilized.

Example 3: Alternative Treatment Method

In this example, a patient suffering from acute pancreatitis is treated as in Example 2, with, the therapeutic agent given continuously over a period of two weeks. After the treatment regimen, autodigestion has ceased, and the patient's pancreas has stabilized.

Example 4: Alternative Treatment Method

In this example, a patient suffering from acute pancreatitis is given a single pharmacologically effective amount of the therapeutic agent of Example 1 by parenteral administration. Two days after the treatment regimen, autodigestion has ceased and the patient's pancreas has stabilized.

It will be understood that the present invention is not to be limited by the embodiments and examples described herein, and that the invention is defined solely by the claims that conclude this specification.

CLAIMS

What is claimed is:

1. A composition for the treatment of acute pancreatitis in a mammal comprising,
   a. a first element comprising a binding element able to specifically bind a pancreatic cell surface marker under physiological conditions,
   b. a second element comprising a translocation element able to facilitate the transfer of a polypeptide across a vesicular membrane, and
   c. a third element comprising a therapeutic element able, when present in the cytoplasm of a pancreatic cell, to inhibit enzymatic secretion by said pancreatic cell.

2. The composition of claim 1 wherein said pancreatic cell is an acinar cell and said cell surface marker is a CCK receptor.

3. The composition of claim 1 wherein said therapeutic element will cleave a SNARE protein and cleavage of said SNARE protein inhibits said secretion.

4. The composition of claim 3 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.

5. The composition of claim 2 wherein said therapeutic element will cleave a SNARE protein, wherein cleavage of said SNARE protein inhibits said secretion.

6. The composition of claim 5 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25 and VAMP.

7. The composition of claim 5 wherein said CCK receptor is the human CCK A receptor.

8. The composition of claim 5 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 6.

9. The composition of claim 8 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 5.

10. The composition of claim 9 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 4.

11. The composition of claim 10 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 3.

12. The composition of claim 11 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO:2.

13. The composition of claim 1 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

14. The composition of claim 13 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

15. The composition of claim 14 wherein said spacer moiety comprises a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

16. The composition of claim 15 wherein said polypeptide comprises an amino acid sequence consisting of SEQ ID NO:11.

17. The composition of claim 7 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

18. The composition of claim 17 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

19. The composition of claim 18 wherein said spacer moiety comprises a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

20. The composition of claim 19 wherein said polypeptide comprises an amino acid sequence consisting of SEQ ID NO:11.

21. The composition of claim 8 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

22. The composition of claim 17 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

23. The composition of claim 18 wherein said spacer moiety comprises a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

24. The composition of claim 19 wherein said polypeptide comprises an amino acid sequence consisting of SEQ ID NO:11.

25. A method for the treatment of a mammal suffering from acute pancreatitis comprising:

administering to said patient a pharmaceutically effective amount of a composition comprising a first element comprising a binding element able to specifically bind a pancreatic cell surface marker under physiological conditions, a second element comprising a translocation element able to facilitate the transfer of a polypeptide across a vesicular membrane, and a third element comprising a therapeutic element able, when present in the cytoplasm of a pancreatic cell, to inhibit enzymatic secretion by said pancreatic cell.

26. The method of claim 25 wherein said pancreatic cell is an acinar cell and said cell surface marker is a CCK receptor.

27. The method of claim 26 wherein said therapeutic element will cleave a SNARE protein and cleavage of said SNARE protein inhibits said secretion.

28. The method of claim 27 wherein said SNARE protein is selected from the group consisting of syntaxin, SNAP-25, and VAMP.

29. The method of claim 28 wherein said CCK receptor is the human CCK A receptor.

30. The method of claim 29 wherein said binding element comprises an amino acid sequence consisting of SEQ ID NO: 6.

31. The method of claim 25 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

32. The method of claim 31 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

33. The method of claim 28 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

34. The method of claim 33 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

35. The method of claim 30 wherein said composition further comprises a spacer moiety separating said binding element from said translocation element.

36. The method of claim 35 wherein said spacer moiety comprises a moiety selected from the group consisting of a hydrocarbon, a polypeptide other than an

immunoglobulin hinge region, and a proline-containing polypeptide identical or analogous to an immunoglobulin hinge region.

37. The method of claim 25 wherein said composition is formulated in an infusion solution, and is administered to said patient intravenously.

38. The method of claim 31 wherein said composition is formulated in an infusion solution, and is administered to said patient intravenously.

39. The method of claim 33 wherein said composition is formulated in an infusion solution, and is administered to said patient intravenously.

40. The method of claim 35 wherein said composition is formulated in an infusion solution, and is administered to said patient intravenously.

ABSTRACT

Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.

COMBINED DECLARATION & POWER OF ATTORNEY - U.S.A Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **METHODS AND COMPOSITIONS FOR THE TREATMENT OF PANCREATITIS** the specification of which

(check one) [X] is attached hereto
[ ] was filed on _____ as US Application Serial No. _____
or PCT International Application No._____
and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, ß1.56(a). I hereby claim foreign priority benefits under 35 USC ß 119(a)-(d) or ß365(b) of any foreign application(s) for patent or inventorís certificate, or ß365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventorís certificate, or PCT International application having a filing date before that of the Prior Foreign Applications(s).

Number	Country	Day/Month/Yr filed)	[ ] Priority Not Claimed
_____	_____	_____	

I hereby claim the benefit under 35 USC ß119 (e) of any United States provisional application(s) listed below.

Application No.	Filing Date
_____	_____

I hereby claim the benefit under Title 35, United States Code, ß120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, ß112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, ß1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filing Date
_____	_____

I hereby appoint **CARLOS A. FISHER, Registration No. 36,510** (to whom all communications are to be directed), and the below-named persons (of the same address) individually and collectively my attorneys to prosecute this application and to transact all

business in the Patent and Trademark Office connected therewith and with the resulting patent, with full power to appoint associate attorneys:

Name	Registration No.
Robert Baran	25,806
Martin A. Voet	25,208

of the following correspondence address: **Allergan, Inc., 2525 Dupont Drive, Irvine, CA. 92612**

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under ß1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR:			
First Name: George	Initial	Last Name Sachs	
RESIDENCE & CITIZENSHIP			
City Encino	State or Foreign Country California	Country of Citizenship USA	
POST OFFICE ADDRESS			
Post Office Address 17986 Boris Drive	City Encino	State or Country CA	Zip Code 91316
SIGNATURE OF INVENTOR G. Sachs		DATE: 4/8/99	
FULL NAME OF INVENTOR:			
First Name: Kei	Initial Roger	Last Name Aoki	
RESIDENCE & CITIZENSHIP			
City Coto de Caza	State or Foreign Country California	Country of Citizenship USA	
POST OFFICE ADDRESS			
Post Office Address 2 Ginger Lily Court	City Coto de Caza	State or Country CA	Zip Code 92679
SIGNATURE OF INVENTOR K. Roger Aoki		DATE: 4/7/99	

37 CFR § 1.56 Duty to Disclose Information Material to Patentability.

A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by Section Section 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

Prior art cited in search reports of a foreign patent office in a counterpart application, and

The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or

It refutes, or is inconsistent with, a position the applicant takes in:

Opposing an argument of unpatentability relied on by the Office, or

Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

Each inventor named in the application;

Each attorney or agent who prepares or prosecutes the application; and

Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

35 USC § 102. Conditions for Patentability; Novelty and Loss of Right to Patent

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or

(c) he has abandoned the invention, or

(d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for
patent, or

(f) he did not himself invent the subject matter sought to be patented, or

(g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 USC § 103. Conditions for Patentability; Non-obvious Subject Matter

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

(b)

(1) Notwithstanding subsection (a), and upon timely election by the applicant for patent to proceed under this subsection, a biotechnological process using or resulting in a composition of matter that is novel under section 102 and nonobvious under subsection (a) of this section shall be considered nonobvious if -

(A) claims to the process and the composition of matter are contained in either the same application for patent or in separate applications having the same effective filing date; and

(B) the composition of matter, and the process at the time it was invented, were owned by the same person or subject to an obligation of assignment to the same person.

(2) A patent issued on a process under paragraph (1) -

(A) shall also contain the claims to the composition of matter used in or made by that process,

or

(B) shall, if such composition of matter is claimed in another patent, be set to expire on the same date as such other patent, notwithstanding section 154.

(3) For purposes of paragraph (1), the term "biotechnological process" means -

(A) a process of genetically altering or otherwise inducing a single- or multi-celled organism to -

(i) express an exogenous nucleotide sequence,

(ii) inhibit, eliminate, augment, or alter expression of an endogenous nucleotide sequence, or

(iii) express a specific physiological characteristic not naturally associated with said organism;

(B) cell fusion procedures yielding a cell line that expresses a specific protein, such as a monoclonal antibody; and

(C) a method of using a product produced by a process defined by subparagraph (A) or (B), or a combination of subparagraphs (A) and (B).

SEQUENCE LISTING

<110> Kei Roger Aoki
George Sachs

<120> Method and Compositions for the
Treatment of Pancreatitis

<130> 17282

<160> 11

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 115
<212> PRT
<213> Homo sapiens

<400> 1

```
Met Asn Ser Gly Val Cys Leu Cys Val Leu Met Ala Val Leu Ala Ala
 1               5                  10                  15
Gly Ala Leu Thr Gln Pro Val Pro Pro Ala Asp Pro Ala Gly Ser Gly
            20                  25                  30
Leu Gln Arg Ala Glu Glu Ala Pro Arg Arg Gln Leu Arg Val Ser Gln
        35                  40                  45
Arg Thr Asp Gly Glu Ser Arg Ala His Leu Gly Ala Leu Leu Ala Arg
    50                  55                  60
Tyr Ile Gln Gln Ala Arg Lys Ala Pro Ser Gly Arg Met Ser Ile Val
65                  70                  75                  80
Lys Asn Leu Gln Asn Leu Asp Pro Ser His Arg Ile Ser Asp Arg Asp
                85                  90                  95
Tyr Met Gly Trp Met Asp Phe Gly Arg Arg Ser Ala Glu Glu Tyr Glu
            100                 105                 110
Tyr Pro Ser
        115
```

<210> 2
<211> 58
<212> PRT
<213> Homo sapiens

<400> 2

```
Val Ser Gln Arg Thr Asp Gly Glu Ser Arg Ala His Leu Gly Ala Leu
 1               5                  10                  15
Leu Ala Arg Tyr Ile Gln Gln Ala Arg Lys Ala Pro Ser Gly Arg Met
            20                  25                  30
Ser Ile Val Lys Asn Leu Gln Asn Leu Asp Pro Ser His Arg Ile Ser
        35                  40                  45
Asp Arg Asp Tyr Met Gly Trp Met Asp Phe
    50                  55
```

<210> 3
<211> 39
<212> PRT
<213> Homo sapiens

<400> 3
Tyr Ile Gln Gln Ala Arg Lys Ala Pro Ser Gly Arg Met Ser Ile Val
1 5 10 15
Lys Asn Leu Gln Asn Leu Asp Pro Ser His Arg Ile Ser Asp Arg Asp
20 25 30
Tyr Met Gly Trp Met Asp Phe
35

<210> 4
<211> 33
<212> PRT
<213> Homo sapiens

<400> 4
Lys Ala Pro Ser Gly Arg Met Ser Ile Val Lys Asn Leu Gln Asn Leu
1 5 10 15
Asp Pro Ser His Arg Ile Ser Asp Arg Asp Tyr Met Gly Trp Met Asp
20 25 30
Phe

<210> 5
<211> 12
<212> PRT
<213> Homo sapiens

<400> 5
Ile Ser Asp Arg Asp Tyr Met Gly Trp Met Asp Phe
1 5 10

<210> 6
<211> 9
<212> PRT
<213> Homo sapiens

<400> 6
Arg Asp Tyr Met Gly Trp Met Asp Phe
1 5

<210> 7
<211> 448
<212> PRT
<213> Clostridium botulinum

<400> 7
Met Pro Phe Val Asn Lys Gln Phe Asn Tyr Lys Asp Pro Val Asn Gly
1 5 10 15
Val Asp Ile Ala Tyr Ile Lys Ile Pro Asn Ala Gly Gln Met Gln Pro
20 25 30
Val Lys Ala Phe Lys Ile His Asn Lys Ile Trp Val Ile Pro Glu Arg
35 40 45
Asp Thr Phe Thr Asn Pro Glu Glu Gly Asp Leu Asn Pro Pro Pro Glu
50 55 60
Ala Lys Gln Val Pro Val Ser Tyr Tyr Asp Ser Thr Tyr Leu Ser Thr
65 70 75 80
Asp Asn Glu Lys Asp Asn Tyr Leu Lys Gly Val Thr Lys Leu Phe Glu
85 90 95

```
Arg Ile Tyr Ser Thr Asp Leu Gly Arg Met Leu Leu Thr Ser Ile Val
            100                 105                 110
Arg Gly Ile Pro Phe Trp Gly Gly Ser Thr Ile Asp Thr Glu Leu Lys
        115                 120                 125
Val Ile Asp Thr Asn Cys Ile Asn Val Ile Gln Pro Asp Gly Ser Tyr
    130                 135                 140
Arg Ser Glu Glu Leu Asn Leu Val Ile Ile Gly Pro Ser Ala Asp Ile
145                 150                 155                 160
Ile Gln Phe Glu Cys Lys Ser Phe Gly His Glu Val Leu Asn Leu Thr
                165                 170                 175
Arg Asn Gly Tyr Gly Ser Thr Gln Tyr Ile Arg Phe Ser Pro Asp Phe
            180                 185                 190
Thr Phe Gly Phe Glu Glu Ser Leu Glu Val Asp Thr Asn Pro Leu Leu
        195                 200                 205
Gly Ala Gly Lys Phe Ala Thr Asp Pro Ala Val Thr Leu Ala His Glu
    210                 215                 220
Leu Ile His Ala Gly His Arg Leu Tyr Gly Ile Ala Ile Asn Pro Asn
225                 230                 235                 240
Arg Val Phe Lys Val Asn Thr Asn Ala Tyr Tyr Glu Met Ser Gly Leu
                245                 250                 255
Glu Val Ser Phe Glu Glu Leu Arg Thr Phe Gly Gly His Asp Ala Lys
            260                 265                 270
Phe Ile Asp Ser Leu Gln Glu Asn Glu Phe Arg Leu Tyr Tyr Tyr Asn
        275                 280                 285
Lys Phe Lys Asp Ile Ala Ser Thr Leu Asn Lys Ala Lys Ser Ile Val
    290                 295                 300
Gly Thr Thr Ala Ser Leu Gln Tyr Met Lys Asn Val Phe Lys Glu Lys
305                 310                 315                 320
Tyr Leu Leu Ser Glu Asp Thr Ser Gly Lys Phe Ser Val Asp Lys Leu
                325                 330                 335
Lys Phe Asp Lys Leu Tyr Lys Met Leu Thr Glu Ile Tyr Thr Glu Asp
            340                 345                 350
Asn Phe Val Lys Phe Phe Lys Val Leu Asn Arg Lys Thr Tyr Leu Asn
        355                 360                 365
Phe Asp Lys Ala Val Phe Lys Ile Asn Ile Val Pro Lys Val Asn Tyr
    370                 375                 380
Thr Ile Tyr Asp Gly Phe Asn Leu Arg Asn Thr Asn Leu Ala Ala Asn
385                 390                 395                 400
Phe Asn Gly Gln Asn Thr Glu Ile Asn Asn Met Asn Phe Thr Lys Leu
                405                 410                 415
Lys Asn Phe Thr Gly Leu Phe Glu Phe Tyr Lys Leu Leu Cys Val Arg
            420                 425                 430
Gly Ile Ile Thr Ser Lys Thr Lys Ser Leu Asp Lys Gly Tyr Asn Lys
        435                 440                 445
```

<210> 8
<211> 423
<212> PRT
<213> Clostridium botulinum

<400> 8

```
Ala Leu Asn Asp Leu Cys Ile Lys Val Asn Asn Trp Asp Leu Phe Phe
 1               5                  10                  15
Ser Pro Ser Glu Asp Asn Phe Thr Asn Asp Leu Asn Lys Gly Glu Glu
            20                  25                  30
Ile Thr Ser Asp Thr Asn Ile Glu Ala Ala Glu Glu Asn Ile Ser Leu
        35                  40                  45
```

```
Asp Leu Ile Gln Gln Tyr Tyr Leu Thr Phe Asn Phe Asp Asn Glu Pro
    50                  55                  60
Glu Asn Ile Ser Ile Glu Asn Leu Ser Ser Asp Ile Ile Gly Gln Leu
65                  70                  75                  80
Glu Leu Met Pro Asn Ile Glu Arg Phe Pro Asn Gly Lys Lys Tyr Glu
                85                  90                  95
Leu Asp Lys Tyr Thr Met Phe His Tyr Leu Arg Ala Gln Glu Phe Glu
            100                 105                 110
His Gly Lys Ser Arg Ile Ala Leu Thr Asn Ser Val Asn Glu Ala Leu
        115                 120                 125
Leu Asn Pro Ser Arg Val Tyr Thr Phe Phe Ser Ser Asp Tyr Val Lys
    130                 135                 140
Lys Val Asn Lys Ala Thr Glu Ala Ala Met Phe Leu Gly Trp Val Glu
145                 150                 155                 160

Gln Leu Val Tyr Asp Phe Thr Asp Glu Thr Ser Glu Val Ser Thr Thr
                165                 170                 175
Asp Lys Ile Ala Asp Ile Thr Ile Ile Ile Pro Tyr Ile Gly Pro Ala
            180                 185                 190
Leu Asn Ile Gly Asn Met Leu Tyr Lys Asp Asp Phe Val Gly Ala Leu
        195                 200                 205
Ile Phe Ser Gly Ala Val Ile Leu Leu Glu Phe Ile Pro Glu Ile Ala
    210                 215                 220
Ile Pro Val Leu Gly Thr Phe Ala Leu Val Ser Tyr Ile Ala Asn Lys
225                 230                 235                 240
Val Leu Thr Val Gln Thr Ile Asp Asn Ala Leu Ser Lys Arg Asn Glu
                245                 250                 255
Lys Trp Asp Glu Val Tyr Lys Tyr Ile Val Thr Asn Trp Leu Ala Lys
            260                 265                 270
Val Asn Thr Gln Ile Asp Leu Ile Arg Lys Lys Met Lys Glu Ala Leu
        275                 280                 285
Glu Asn Gln Ala Glu Ala Thr Lys Ala Ile Ile Asn Tyr Gln Tyr Asn
    290                 295                 300
Gln Tyr Thr Glu Glu Glu Lys Asn Asn Ile Asn Phe Asn Ile Asp Asp
305                 310                 315                 320
Leu Ser Ser Lys Leu Asn Glu Ser Ile Asn Lys Ala Met Ile Asn Ile
                325                 330                 335
Asn Lys Phe Leu Asn Gln Cys Ser Val Ser Tyr Leu Met Asn Ser Met
            340                 345                 350
Ile Pro Tyr Gly Val Lys Arg Leu Glu Asp Phe Asp Ala Ser Leu Lys
        355                 360                 365
Asp Ala Leu Leu Lys Tyr Ile Tyr Asp Asn Arg Gly Thr Leu Ile Gly
    370                 375                 380
Gln Val Asp Arg Leu Lys Asp Lys Val Asn Asn Thr Leu Ser Thr Asp
385                 390                 395                 400
Ile Pro Phe Gln Leu Ser Lys Tyr Val Asp Asn Gln Arg Leu Leu Ser
                405                 410                 415
Thr Phe Thr Glu Tyr Ile Lys
            420
```

<210> 9
<211> 382
<212> PRT
<213> Clostridium botulinum

<400> 9
Gln Leu Phe Asn Leu Glu Ser Ser Lys Ile Glu Val Ile Leu Lys Asn

```
 1               5                  10                  15
Ala Ile Val Tyr Asn Ser Met Tyr Glu Asn Phe Ser Thr Ser Phe Trp
            20                  25                  30
Ile Arg Ile Pro Lys Tyr Phe Asn Ser Ile Ser Leu Asn Asn Glu Tyr
        35                  40                  45
Thr Ile Ile Asn Cys Met Glu Asn Asn Ser Gly Trp Lys Val Ser Leu
    50                  55                  60
Asn Tyr Gly Glu Ile Ile Trp Thr Leu Gln Asp Thr Gln Glu Ile Lys
65                  70                  75                  80
Gln Arg Val Val Phe Lys Tyr Ser Gln Met Ile Asn Ile Ser Asp Tyr
                85                  90                  95
Ile Asn Arg Trp Ile Phe Val Thr Ile Thr Asn Asn Arg Leu Asn Asn
            100                 105                 110
Ser Lys Ile Tyr Ile Asn Gly Arg Leu Ile Asp Gln Lys Pro Ile Ser
        115                 120                 125
Asn Leu Gly Asn Ile His Ala Ser Asn Asn Ile Met Phe Lys Leu Asp
    130                 135                 140
Gly Cys Arg Asp Thr His Arg Tyr Ile Trp Ile Lys Tyr Phe Asn Leu
145                 150                 155                 160

Phe Asp Lys Glu Leu Asn Glu Lys Glu Ile Lys Asp Leu Tyr Asp Asn
                165                 170                 175
Gln Ser Asn Ser Gly Ile Leu Lys Asp Phe Trp Gly Asp Tyr Leu Gln
            180                 185                 190
Tyr Asp Lys Pro Tyr Tyr Met Leu Asn Leu Tyr Asp Pro Asn Lys Tyr
        195                 200                 205
Val Asp Val Asn Asn Val Gly Ile Arg Gly Tyr Met Tyr Leu Lys Gly
    210                 215                 220
Pro Arg Gly Ser Val Met Thr Thr Asn Ile Tyr Leu Asn Ser Ser Leu
225                 230                 235                 240
Tyr Arg Gly Thr Lys Phe Ile Ile Lys Lys Tyr Ala Ser Gly Asn Lys
                245                 250                 255
Asp Asn Ile Val Arg Asn Asn Asp Arg Val Tyr Ile Asn Val Val Val
            260                 265                 270
Lys Asn Lys Glu Tyr Arg Leu Ala Thr Asn Ala Ser Gln Ala Gly Val
        275                 280                 285
Glu Lys Ile Leu Ser Ala Leu Glu Ile Pro Asp Val Gly Asn Leu Ser
    290                 295                 300
Gln Val Val Val Met Lys Ser Lys Asn Asp Gln Gly Ile Thr Asn Lys
305                 310                 315                 320
Cys Lys Met Asn Leu Gln Asp Asn Asn Gly Asn Asp Ile Gly Phe Ile
                325                 330                 335
Gly Phe His Gln Phe Asn Asn Ile Ala Lys Leu Val Ala Ser Asn Trp
            340                 345                 350
Tyr Asn Arg Gln Ile Glu Arg Ser Ser Arg Thr Leu Gly Cys Ser Trp
        355                 360                 365
Glu Phe Ile Pro Val Asp Asp Gly Trp Gly Glu Arg Pro Leu
    370                 375                 380
```

<210> 10
<211> 4835
<212> DNA
<213> Clostridium botulinum

<400> 10
aagcttctaa atttaaatta ttaagtataa atccaaataa acaatatgtt caaaaacttg 60
atgaggtaat aatttctgta ttagataata tggaaaaata tatagatata tctgaagata 120

atagattgca actaatagat aacaaaaata acgcaaagaa gatgataatt agtaatgata 180
tatttatttc caattgttta accctatctt ataacggtaa atatatatgt ttatctatga 240
aagatgaaaa ccataattgg atgatatgta ataatgatat gtcaaagtat ttgtatttat 300
ggtcatttaa ataattaata atttaattaa ttttaaatat tataagaggt gttaaatatg 360
ccatttgtta ataaacaatt taattataaa gatcctgtaa atggtgttga tattgcttat 420
ataaaaattc caaatgcagg acaaatgcaa ccagtaaaag cttttaaaat tcataataaa 480
atatgggtta ttccagaaag agatacattt acaaatcctg aagaaggaga tttaaatcca 540
ccaccagaag caaaacaagt tccagtttca tattatgatt caacatattt aagtacagat 600
aatgaaaaag ataattattt aaagggagtt acaaaattat ttgagagaat ttattcaact 660
gatcttggaa gaatgttgtt aacatcaata gtaaggggaa taccattttg ggtggaagt 720
acaatagata cagaattaaa agttattgat actaattgta ttaatgtgat acaaccagat 780
ggtagttata gatcagaaga acttaatcta gtaataatag gaccctcagc tgatattata 840
cagtttgaat gtaaaagctt tggacatgaa gttttgaatc ttacgcgaaa tggttatggc 900
tctactcaat acattagatt tagcccagat tttacatttg gttttgagga gtcacttgaa 960
gttgatacaa atcctctttt aggtgcaggc aaatttgcta cagatccagc agtaacatta 1020
gcacatgaac ttatacatgc tggacataga ttatatggaa tagcaattaa tccaaatagg 1080
gtttttaaag taaatactaa tgcctattat gaaatgagtg ggttagaagt aagctttgag 1140
gaacttagaa catttgggggg acatgatgca aagtttatag atagtttaca ggaaaacgaa 1200
tttcgtctat attattataa taagtttaaa gatatagcaa gtacacttaa taaagctaaa 1260
tcaatagtag gtactactgc ttcattacag tatatgaaaa atgtttttaa agagaaatat 1320
ctcctatctg aagatacatc tggaaaattt tcggtagata aattaaaatt tgataagtta 1380
tacaaaatgt taacagagat ttacacagag gataattttg ttaagttttt taaagtactt 1440
aacagaaaaa catatttgaa ttttgataaa gccgtattta agataaatat agtacctaag 1500
gtaaattaca caatatatga tggatttaat ttaagaaata caaatttagc agcaaacttt 1560
aatggtcaaa atacagaaat taataatatg aattttacta aactaaaaaa ttttactgga 1620
ttgtttgaat tttataagtt gctatgtgta agagggataa taacttctaa aactaaatca 1680
ttagataaag gatacaataa ggcattaaat gatttatgta tcaaagttaa taattgggac 1740
ttgtttttta gtccttcaga agataatttt actaatgatc taaataaagg agaagaaatt 1800
acatctgata ctaatataga agcagcagaa gaaaatatta gtttagattt aatacaacaa 1860
tattatttaa cctttaattt tgataatgaa cctgaaaata tttcaataga aaatctttca 1920
agtgacatta taggccaatt agaacttatg cctaatatag aaagatttcc taatggaaaa 1980
aagtatgagt tagataaata tactatgttc cattatcttc gtgctcaaga atttgaacat 2040
ggtaaatcta ggattgcttt aacaaattct gttaacgaag cattattaaa tcctagtcgt 2100
gtttatacat ttttttcttc agactatgta aagaaagtta ataaagctac ggaggcagct 2160
atgtttttag gctgggtaga acaattagta tatgatttta ccgatgaaac tagcgaagta 2220
agtactacgg ataaaattgc ggatataact ataattattc catatatagg acctgcttta 2280
aatataggta atatgttata taaagatgat tttgtaggtg ctttaatatt ttcaggagct 2340
gttattctgt tagaatttat accagagatt gcaatacctg tattaggtac ttttgcactt 2400
gtatcatata ttgcgaataa ggttctaacc gttcaaacaa tagataatgc tttaagtaaa 2460
agaaatgaaa aatgggatga ggtctataaa tatatagtaa caaattggtt agcaaaggtt 2520
aatacacaga ttgatctaat aagaaaaaaa atgaaagaag ctttagaaaa tcaagcagaa 2580
gcaacaaagg ctataataaa ctatcagtat aatcaatata ctgaggaaga gaaaaataat 2640
attaatttta atattgatga tttaagttcg aaacttaatg agtctataaa taaagctatg 2700
attaatataa ataaattttt gaatcaatgc tctgtttcat atttaatgaa ttctatgatc 2760
ccttatggtg ttaaacggtt agaagatttt gatgctagtc ttaaagatgc attattaaag 2820
tatatatatg ataatagagg aactttaatt ggtcaagtag atagattaaa agataaagtt 2880
aataatacac ttagtacaga tatacctttt cagctttcca aatacgtaga taatcaaaga 2940
ttattatcta catttactga atatattaag aatattatta atacttctat attgaattta 3000
agatatgaaa gtaatcattt aatagactta tctaggtatg catcaaaaat aaatattggt 3060
agtaaagtaa attttgatcc aatagataaa aatcaaattc aattatttaa tttagaaagt 3120
agtaaaattg aggtaatttt aaaaaatgct attgtatata atagtatgta tgaaaatttt 3180
agtactagct tttggataag aattcctaag tattttaaca gtataagtct aaataatgaa 3240
tatacaataa taaattgtat ggaaaataat tcaggatgga aagtatcact taattatggt 3300
gaaataatct ggactttaca ggatactcag gaaataaaac aaagagtagt ttttaaatac 3360
agtcaaatga ttaatatatc agattatata aacagatgga tttttgtaac tatcactaat 3420
aatagattaa ataactctaa aatttatata aatggaagat taatagatca aaaaccaatt 3480
tcaaatttag gtaatattca tgctagtaat aatataatgt ttaaattaga tggttgtaga 3540

gatacacata gatatatttg gataaaatat tttaatcttt ttgataagga attaaatgaa 3600
aaagaaatca aagatttata tgataatcaa tcaaattcag gtattttaaa agacttttgg 3660
ggtgattatt tacaatatga taaaccatac tatatgttaa atttatatga tccaaataaa 3720
tatgtcgatg taaataatgt aggtattaga ggttatatgt atcttaaagg gcctagaggt 3780
agcgtaatga ctacaaacat ttatttaaat tcaagtttgt atagggggac aaaatttatt 3840
ataaaaaaat atgcttctgg aaataaagat aatattgtta gaaataatga tcgtgtatat 3900
attaatgtag tagttaaaaa taaagaatat aggttagcta ctaatgcatc acaggcaggc 3960
gtagaaaaaa tactaagtgc attagaaata cctgatgtag gaaatctaag tcaagtagta 4020
gtaatgaagt caaaaaatga tcaaggaata acaaataaat gcaaaatgaa tttacaagat 4080
aataatggga atgatatagg ctttatagga tttcatcagt ttaataatat agctaaacta 4140
gtagcaagta attggtataa tagacaaata gaaagatcta gtaggacttt gggttgctca 4200
tgggaattta ttcctgtaga tgatggatgg ggagaaaggc cactgtaatt aatctcaaac 4260
tacatgagtc tgtcaagaat tttctgtaaa catccataaa aattttaaaa ttaatatgtt 4320
taagaataac tagatatgag tattgtttga actgcccctg tcaagtagac aggtaaaaaa 4380
ataaaaatta agatactatg gtctgatttc gatattctat cggagtcaga ccttttaact 4440
tttcttgtat cctttttgta ttgtaaaact ctatgtattc atcaattgca agttccaatt 4500
agtcaaaatt atgaaacttt ctaagataat acatttctga ttttataatt tcccaaaatc 4560
cttccatagg accattatca atacatctac caactcgaga catactttga gttgcgccta 4620
tctcattaag tttattcttg aaagatttac ttgtatattg aaaaccgcta tcactgtgaa 4680
aaagtggact agcatcagga ttggaggtaa ctgctttatc aaaggtttca aagacaagga 4740
cgttgttatt tgattttcca agtacatagg aaataatgct attatcatgc aaatcaagta 4800
tttcactcaa gtacgccttt gtttcgtctg ttaac 4835

<210> 11
<211> 15
<212> PRT
<213> Homo sapiens

<400> 11
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro
1 5 10 15